United States Image-guided Therapy Systems Market Report by Product, Application, End Use, States and Company Analysis, 2026-2034

United States Image-guided Therapy Systems Market Size and Forecast 2026-2034

United States Image-guided Therapy Systems Market is expected to reach US$ 2.47 Billion by 2034 from US$ 1.57 Billion in 2025, with a CAGR of 5.18% from 2026 to 2034. Growing adoption of minimally invasive procedures, increasing demand for real-time visualization, AI-enabled imaging, surgical navigation, interventional cardiology, oncology procedures, and integrated operating-room technologies is accelerating image-guided therapy systems adoption across the United States.

United States Image-guided Therapy Systems Industry Overview

The United States image-guided therapy systems industry is expanding as healthcare providers increasingly use real-time imaging to improve precision during minimally invasive and interventional procedures. These systems combine imaging modalities, navigation, treatment planning, visualization, and increasingly artificial intelligence to help clinicians guide instruments and therapeutic devices with greater accuracy. Major applications include interventional cardiology, vascular procedures, oncology, neurosurgery, orthopedics, and minimally invasive surgery. Fluoroscopy, computed tomography, ultrasound, magnetic resonance imaging, endoscopy, and hybrid imaging technologies can provide anatomical information during procedures rather than relying exclusively on preoperative scans. The growing emphasis on precision medicine and less-invasive treatment is encouraging hospitals to invest in advanced image-guided platforms.

Technology development is increasingly focused on integrating imaging with software, navigation, robotics, and clinical decision support. In May 2026, Siemens Healthineers received FDA clearance for six new Artis interventional systems incorporating its Optiq AI imaging chain, which uses AI to analyze and optimize image data in real time. Philips also received U.S. FDA 510(k) clearance in March 2026 for EchoNavigator R5.0 with DeviceGuide, an AI-powered solution designed to track and visualize mitral-valve repair devices during minimally invasive procedures and integrate with its Azurion image-guided therapy platform. These developments illustrate the industry's movement toward intelligent, connected intervention environments that combine imaging and procedural information within unified workflows. GE HealthCare has similarly expanded integration between intraoperative ultrasound and surgical navigation.

Market expansion is supported by rising procedure volumes, an aging population, cardiovascular disease, cancer, and demand for shorter hospital stays and minimally invasive interventions. Hospitals are increasingly seeking systems that can improve procedural accuracy while reducing workflow complexity and supporting efficient utilization of expensive operating and interventional rooms. GE HealthCare announced upgrade pathways for selected Allia and Innova systems in June 2026, allowing healthcare providers to modernize existing interventional suites while preserving infrastructure and reducing major construction requirements. California, Texas, New York, and Florida represent important regional markets because of their extensive hospital networks, academic medical centers, specialty hospitals, and advanced surgical infrastructure. Endoscopic imaging, cardiac interventions, and hospital-based procedures remain major opportunities. However, high capital expenditure, specialized training, interoperability requirements, maintenance costs, radiation-management considerations, and reimbursement pressures can constrain adoption. Continued development of AI-enabled imaging, integrated navigation, compact systems, and software-driven upgrades is expected to strengthen the market.

Growth Drivers for the United States Image-guided Therapy Systems Market

Rising Adoption of Minimally Invasive Procedures

The increasing preference for minimally invasive treatment is a fundamental driver of image-guided therapy systems in the United States. Procedures performed through small incisions or catheter-based access require accurate visualization of anatomy, instruments, and therapeutic devices. Image-guided platforms enable clinicians to monitor anatomy and device position in real time, supporting more precise interventions while potentially reducing tissue trauma and recovery time. Interventional cardiology, vascular treatment, oncology, neurosurgery, and other specialties increasingly rely on imaging during procedures. AI-enabled systems are further improving image quality and providing additional procedural information. Siemens Healthineers' 2026 FDA-cleared Artis systems, for example, use AI within the imaging chain to analyze and optimize live image data. As healthcare providers prioritize shorter hospital stays, improved procedural precision, and less invasive treatment pathways, investment in image-guided platforms is expected to increase. Hospitals are also seeking multifunctional systems that can serve several specialties, improving utilization of expensive interventional infrastructure.

Integration of AI and Advanced Visualization

Artificial intelligence and advanced visualization are transforming image-guided therapy by enabling systems to process imaging information and provide more actionable insights during procedures. Traditional imaging provides anatomical visualization, whereas AI-enabled platforms can assist with image optimization, device tracking, segmentation, workflow support, and treatment planning. In March 2026, Philips received FDA clearance for EchoNavigator R5.0 with DeviceGuide, which uses AI to track and visualize mitral-valve repair devices during minimally invasive procedures. Siemens also incorporated AI into its Optiq imaging chain to optimize live images across newly cleared Artis systems. Such developments can improve visualization while potentially reducing cognitive and workflow burdens on clinicians. The increasing availability of AI-enabled medical devices across radiology and cardiovascular applications further supports this trend. As algorithms become more integrated into clinical platforms, healthcare providers are likely to favor systems capable of combining imaging, navigation, analytics, and procedural guidance within a single environment.

Growing Cardiovascular and Oncology Intervention Volumes

Increasing demand for cardiovascular and oncology interventions is strengthening the addressable market for image-guided therapy systems. Cardiovascular procedures frequently require continuous visualization of vessels, anatomical structures, catheters, guidewires, and implanted devices. Similarly, image guidance is increasingly important in minimally invasive cancer treatments, including ablation, biopsy, embolization, and radiation-related interventions. Real-time imaging can help physicians accurately target diseased tissue while limiting unnecessary damage to surrounding structures. Advanced systems also allow multiple forms of information to be incorporated into procedural workflows. Philips' IntraSight Plus, launched in the United States in March 2026, combines diagnostic and treatment-planning tools for coronary interventions. Increasing clinical complexity is encouraging hospitals to upgrade aging imaging infrastructure and seek more flexible platforms. GE HealthCare's 2026 upgrade pathways for existing interventional suites demonstrate the demand for modernization without complete room replacement.

Challenges in the United States Image-guided Therapy Systems Market

High Capital Investment and Infrastructure Requirements

High acquisition and implementation costs remain a significant barrier to image-guided therapy system adoption. Advanced interventional imaging platforms can require substantial investment in imaging equipment, operating-room or catheterization-laboratory modifications, software, networking, radiation protection, installation, and ongoing service contracts. Hospitals must also consider the opportunity cost of taking procedure rooms offline during installation or major upgrades. Infrastructure requirements can be particularly demanding for hybrid systems involving advanced imaging, robotics, or specialized navigation technologies. Smaller hospitals and healthcare facilities may find these investments difficult to justify when procedure volumes are limited. GE HealthCare's June 2026 upgrade pathways demonstrate an industry response to this challenge by allowing selected healthcare providers to modernize existing systems rather than completely replace infrastructure. Vendors increasingly need to offer scalable upgrade options, financing models, modular platforms, and software improvements that extend equipment lifecycles. Demonstrating measurable clinical and operational returns will remain important for purchasing decisions.

Workflow Complexity, Training, and Interoperability

Image-guided therapy systems increasingly combine imaging, navigation, AI, robotics, patient monitoring, and treatment-planning software, creating complex clinical workflows. Physicians, radiologic technologists, nurses, biomedical engineers, and other personnel require specialized training to operate these systems safely and efficiently. Interoperability can also become challenging when equipment from different manufacturers needs to exchange imaging, navigation, or patient information. Inconsistent interfaces and disconnected software can increase procedural complexity rather than reduce it. AI-enabled technologies introduce additional requirements involving algorithm validation, software updates, cybersecurity, and clinical oversight. The FDA's growing list of AI-enabled medical devices illustrates the rapid expansion of software-assisted technologies across radiology and cardiovascular care. Healthcare providers must therefore establish training programs and standardized workflows while maintaining regulatory and cybersecurity compliance. Manufacturers that deliver intuitive interfaces, seamless interoperability, automated workflow features, and strong technical support can gain an advantage as hospitals increasingly digitize interventional environments.

California Image-guided Therapy Systems Market - Technology-intensive Interventional Ecosystem

California represents a major U.S. market for image-guided therapy systems because of its concentration of advanced hospitals, academic medical centers, specialty healthcare providers, biotechnology companies, and high-volume interventional programs. Major metropolitan areas including Los Angeles, San Francisco, San Diego, and Sacramento support sophisticated cardiovascular, oncology, neurosurgical, and vascular services. Healthcare institutions in the state are strong adopters of advanced imaging, robotics, navigation, AI, and minimally invasive treatment technologies. The state's technology ecosystem also encourages collaboration between healthcare providers and medical-device developers, supporting clinical evaluation of emerging image-guided solutions. Cardiovascular interventions and minimally invasive cancer procedures provide important opportunities for image-guided platforms. Providers increasingly seek integrated systems that can improve imaging quality, procedural efficiency, and navigation. High capital expenditure and operating-room infrastructure requirements remain constraints, particularly for smaller facilities. However, major academic and specialty centers should continue supporting demand for advanced image-guided therapy systems.

Texas Image-guided Therapy Systems Market - Large-scale Healthcare Investment

Texas is an important image-guided therapy systems market because of its extensive hospital infrastructure, major medical centers, cancer institutions, cardiovascular programs, and growing healthcare investment. Houston, Dallas-Fort Worth, Austin, and San Antonio are key centers for advanced interventional and surgical procedures. The state's large healthcare systems provide opportunities for cardiovascular imaging, minimally invasive oncology, vascular intervention, neurosurgery, and image-guided surgery. High procedure volumes can improve utilization of advanced imaging infrastructure and support investments in multifunctional platforms. Texas healthcare providers are also increasingly interested in technologies that improve procedural efficiency and allow facilities to modernize existing interventional rooms. AI-assisted imaging and integrated navigation can help clinicians manage complex procedures while improving visualization. However, implementation costs, training requirements, and differences in technology availability between major metropolitan centers and smaller facilities can influence adoption. Vendors providing scalable systems, upgrade pathways, service coverage, and training can benefit from Texas's expanding healthcare ecosystem.

New York Image-guided Therapy Systems Market - Advanced Cardiovascular and Oncology Care

New York offers significant opportunities for image-guided therapy systems because of its concentration of academic medical centers, hospitals, specialty treatment facilities, cancer centers, and cardiovascular programs. New York City in particular supports high volumes of complex minimally invasive procedures requiring sophisticated imaging and navigation technologies. Image-guided systems are increasingly important for interventional cardiology, structural heart procedures, vascular interventions, oncology, and neurosurgery. Academic institutions also contribute to clinical research and evaluation of emerging AI-assisted imaging and minimally invasive technologies. Healthcare providers are seeking platforms that integrate real-time imaging with treatment planning and procedural guidance, potentially improving workflow consistency. Philips' 2026 developments in AI-supported cardiovascular intervention illustrate the industry's emphasis on integrated image-guided workflows. New York's high healthcare costs and sophisticated infrastructure create both opportunities and purchasing pressures. Vendors with strong clinical evidence, interoperability, service support, and advanced visualization capabilities can address the needs of the state's leading healthcare institutions.

Florida Image-guided Therapy Systems Market - Expanding Interventional Care Capacity

Florida's image-guided therapy systems market is supported by extensive hospital networks, specialized cardiovascular and cancer centers, academic institutions, and increasing demand for minimally invasive treatment. Miami, Tampa, Orlando, and Jacksonville are important healthcare centers with capabilities across cardiology, oncology, vascular intervention, and surgery. The state's large and growing healthcare infrastructure creates demand for systems that can support high procedure volumes while maintaining efficient operating-room workflows. Image-guided platforms are increasingly valuable for catheter-based cardiovascular procedures, tumor interventions, biopsies, and other minimally invasive treatments. Ambulatory and outpatient care models can also create demand for compact and flexible imaging technologies. Florida providers may favor systems offering modular upgrades, intuitive operation, and strong technical support because these capabilities can reduce disruption during technology modernization. Nevertheless, capital constraints, staffing requirements, and infrastructure needs can influence purchasing decisions. Continued expansion of specialized healthcare services should provide opportunities for image-guided therapy manufacturers.

Endoscope Market - Visualization at the Point of Intervention

Endoscopes represent an important component of image-guided therapy because they allow clinicians to directly visualize internal anatomy while performing minimally invasive diagnostic and therapeutic procedures. Modern endoscopic platforms increasingly incorporate high-definition or 4K imaging, three-dimensional visualization, narrow-band imaging, fluorescence, digital enhancement, and other technologies designed to improve tissue visualization. These capabilities support applications across gastroenterology, pulmonology, urology, gynecology, and surgery. The evolution toward integrated imaging platforms is also creating opportunities for image-guided interventions in which visualization is combined with therapeutic instruments and real-time procedural information. Olympus, for example, continues to develop advanced surgical visualization technologies, while the broader industry is integrating imaging with navigation and digital workflow platforms. Demand is supported by increasing preference for minimally invasive procedures and shorter recovery times. However, endoscopic equipment can require substantial capital investment, specialized training, sterilization or reprocessing infrastructure, and regular maintenance. Disposable and single-use technologies may provide additional growth opportunities by addressing infection-control and workflow considerations.

Cardiac Surgery Market - Precision Guidance for Cardiovascular Interventions

Cardiac surgery and interventional cardiology represent important applications for image-guided therapy systems because accurate visualization is essential when navigating catheters, guidewires, implants, and other devices through complex cardiovascular anatomy. Fluoroscopy, intravascular imaging, echocardiography, and advanced image-fusion technologies can help clinicians plan and guide procedures while reducing uncertainty. Structural heart interventions are particularly relevant as minimally invasive approaches expand for conditions such as valvular disease. Philips received FDA clearance in March 2026 for its AI-powered DeviceGuide solution designed to track and visualize mitral-valve repair devices during minimally invasive procedures, illustrating the increasing integration of AI and real-time guidance. Philips also launched IntraSight Plus for coronary interventions, combining diagnostic and treatment-planning capabilities. Continued cardiovascular disease burden, an aging population, and advances in catheter-based therapies should support demand. High equipment costs, radiation exposure considerations, and specialized training remain important challenges.

Hospitals Market - Core Purchasers of Integrated Intervention Platforms

Hospitals represent the principal end-user segment for image-guided therapy systems because they conduct a broad range of complex interventional, surgical, cardiovascular, neurological, and oncology procedures. Large hospitals and academic medical centers often maintain dedicated catheterization laboratories, hybrid operating rooms, interventional radiology suites, and specialized surgical environments capable of supporting advanced imaging platforms. Hospitals increasingly seek systems that integrate imaging, navigation, AI, robotics, and treatment-planning software to improve procedural efficiency and maximize infrastructure utilization. Aging installed equipment is also encouraging modernization. GE HealthCare's 2026 Allia upgrade pathways were specifically designed to help health systems modernize selected interventional systems while preserving existing infrastructure and minimizing disruption. Larger institutions generally have greater capital resources and higher procedure volumes, making them early adopters of advanced systems. Community hospitals may prioritize portable, modular, or upgradeable solutions. Overall, hospital investment will depend on clinical demand, capital budgets, procedure volumes, reimbursement, staffing, and evidence of improved outcomes or operational efficiency.

Research Methodology of the United States Image-guided Therapy Systems Market

1. Market Definition and Scope

• The market was defined by identifying medical systems and technologies that used real-time or pre-acquired imaging to guide therapeutic procedures, interventions, and surgery.
• The scope included imaging equipment, image-guidance platforms, navigation systems, treatment-planning and visualization software, and relevant integrated systems.
• Technologies considered included:
  • X-ray and fluoroscopy-guided systems
  • Ultrasound-guided therapy systems
  • CT-guided intervention systems
  • MRI-guided therapy systems
  • Image-guided endoscopic systems
  • Image-guided radiation therapy systems, where included in the selected scope
  • Navigation, image-fusion, and visualization technologies
• Diagnostic imaging equipment used exclusively for routine diagnosis was excluded unless it formed part of an eligible therapeutic guidance system.
• Standalone surgical robots, general-purpose imaging equipment, and consumables were included only when directly attributable to the defined market.
• The market was measured using annual revenue generated in the United States, expressed in US$ million or billion.

2. Bottom-Up Market Estimation Approach

• The bottom-up approach was used to calculate market revenue by estimating sales of individual image-guided therapy systems and related eligible components.
• Equipment shipments, installations, average selling prices, software sales, and eligible service revenue were assessed by product category.
• Revenue was calculated separately for each major product and application segment.

Core formula:

• Market Revenue = Systems Sold × Average Selling Price (ASP) + Eligible Software Revenue + Eligible Service Revenue

• The number of systems sold or installed annually was estimated using manufacturer disclosures, procurement announcements, hospital purchases, distributor information, and interviews with industry participants.
• ASPs were estimated using publicly available contract awards, tender prices, product quotations, company disclosures, and expert interviews.
• Replacement systems, new installations, and upgrades were evaluated separately to avoid double counting.
• Revenue from software, maintenance, and service contracts was included only when it fell within the defined market scope and was not already bundled into equipment sales.

3. Top-Down Market Estimation Approach

• The top-down approach began with the relevant medical imaging, image-guided intervention, surgical navigation, and therapeutic equipment markets in the United States.
• The total addressable equipment and technology revenue was narrowed to the portion specifically attributable to image-guided therapeutic procedures.
• Revenue shares were assigned based on product functionality, intended use, application, and the proportion of equipment revenue associated with therapeutic guidance.
• General diagnostic imaging, unrelated medical equipment, and systems used exclusively for non-therapeutic purposes were excluded.

Core formula:

• Image-Guided Therapy Systems Market = Relevant Medical Technology Market × Image-Guided Therapy Share
• The estimated market was cross-checked against manufacturer revenues, product-level sales, installed-base information, and U.S. healthcare procurement activity.
• Market shares from broader imaging or surgical navigation categories were applied only after adjusting for differences in market definitions and product coverage.

4. Demand and Installed-Base Assessment

• The installed base of eligible systems across U.S. hospitals, ambulatory surgical centers, specialty clinics, cancer treatment facilities, and other relevant healthcare institutions was assessed.
• New installations, replacement cycles, equipment upgrades, and expansion of interventional facilities were evaluated to determine annual demand.
• Procedure volumes in cardiology, neurosurgery, orthopedics, oncology, urology, gastroenterology, and interventional radiology were considered where they directly supported purchases of image-guided systems.
• Demand was assessed according to facility size, clinical specialty, equipment utilization, and the availability of capital budgets.
• U.S. Census Bureau healthcare establishment statistics were used as contextual inputs for healthcare facility analysis, rather than as direct measures of image-guided therapy system revenue.

5. Product-Type Segmentation

• The market was segmented by the principal imaging modality and guidance technology used during therapeutic procedures.
• The following categories were assessed:
  • CT-based systems
  • Ultrasound-based systems
  • MRI-based systems
  • X-ray and fluoroscopy systems
  • Endoscopic imaging systems
  • Image-guided radiation therapy systems
  • Navigation, image-fusion, and visualization platforms
• Revenue was allocated according to the principal product function and the market's defined classification rules.
• Integrated systems supporting multiple imaging modalities were assigned consistently to avoid counting the same system in multiple product categories.

6. Application-Based Estimation

• Market revenue was analyzed across clinical applications in which imaging actively supported treatment delivery, intervention, or surgical navigation.
• Relevant applications included:
  • Cardiac and vascular procedures
  • Neurosurgery
  • Orthopedic surgery
  • Oncology procedures and tumor ablation
  • Interventional radiology
  • Urology
  • Gastroenterology
  • Image-guided radiation therapy
  • Other eligible minimally invasive procedures
• The analysis considered the number of relevant procedures, adoption of image-guidance technology, equipment requirements, and average system value for each application.
• Application-level revenue was reconciled with product-level estimates to ensure that total market revenue remained consistent.

7. End-User Analysis

• Revenue was categorized by the main purchasing and operating institutions:
  • Hospitals
  • Ambulatory surgical centers
  • Specialty clinics
  • Cancer treatment centers
  • Academic and research institutions, where applicable
• Hospital procurement budgets, capital equipment replacement plans, specialty procedure capacity, and adoption of minimally invasive techniques were evaluated.
• Large hospitals and specialized treatment centers were assessed separately from smaller facilities because of differences in procedure volumes, equipment complexity, and purchasing capacity.
• The analysis distinguished equipment purchases from revenue generated through clinical procedures to avoid mixing equipment-market revenue with healthcare-service revenue.

8. Pricing and Revenue Assessment

• Average selling prices were estimated separately for different imaging modalities, system configurations, and levels of technological sophistication.
• Pricing analysis considered:
  • New equipment versus refurbished systems, where included
  • Standard versus advanced navigation and visualization features
  • Software licensing and image-fusion capabilities
  • Installation and integration costs
  • Maintenance and service agreements
  • System upgrades and replacement components
• Manufacturer quotations, public procurement records, distributor discussions, and hospital purchasing information were used to establish realistic pricing ranges.
• Revenue was recorded at a consistent market level, preferably manufacturer or supplier revenue, to avoid double counting distributor margins and hospital expenditure.

9. Competitive Landscape and Company Revenue

• Major manufacturers and technology providers were assessed based on product portfolios, U.S. commercial presence, system installations, regulatory clearances, partnerships, and product launches.
• Relevant companies included Philips, Siemens Healthineers, GE HealthCare, Medtronic, Brainlab, Varian, Olympus, Stryker, and other suppliers with qualifying products.
• Company-wide revenue was not treated as equivalent to image-guided therapy revenue.
• Instead, eligible product-line sales were identified and adjusted to reflect U.S. sales and the defined market scope.
• Market shares were calculated by dividing each company's estimated eligible U.S. revenue by total market revenue.

10. Primary and Secondary Research

Primary research

• Interviews were conducted with medical device manufacturers, distributors, hospital procurement managers, interventional radiologists, surgeons, biomedical engineers, and healthcare technology specialists.
• Discussions focused on equipment prices, annual shipments, installed bases, replacement cycles, adoption rates, purchasing trends, and competitive positioning.
• Estimates were cross-checked with participants from different parts of the supply chain.

Secondary research

• Company annual reports, investor presentations, product catalogues, regulatory records, procurement announcements, clinical technology publications, and healthcare facility data were reviewed.
• The FDA's 510(k) database and Devices@FDA were used to identify relevant products, applicants, device descriptions, and regulatory decisions.
• The National Institute of Biomedical Imaging and Bioengineering and the National Cancer Institute were consulted for background on image-guided interventions and therapeutic applications.

11. Market Forecasting

• Historical revenue and the estimated base-year market size were used to prepare forecasts for the selected forecast period.
• Key forecasting variables included:
  • Growth in image-guided and minimally invasive procedures
  • Adoption of advanced imaging and navigation technologies
  • Hospital capital expenditure and equipment replacement
  • Expansion of oncology and interventional treatment capacity
  • Integration of artificial intelligence, robotics, and image-fusion software
  • Equipment pricing, reimbursement conditions, and regulatory developments
• Forecast assumptions were tested against historical growth, company guidance, product launches, and expected purchasing cycles.
• Base-case, high-growth, and low-growth scenarios were developed where uncertainty around adoption or equipment investment materially affected the results.

CAGR formula:

• CAGR = [(Ending-Year Market Size ÷ Base-Year Market Size) ^ (1 ÷ Number of Years) − 1] × 100

12. Market Validation and Reconciliation

• Bottom-up estimates were compared with top-down calculations to identify gaps in product coverage, pricing, and annual sales volumes.
• Estimates were reconciled by product type, application, end user, and supplier.
• Equipment sales, software revenue, services, and bundled contracts were checked for overlap.
• Imported equipment, domestic manufacturing, exports, inventory changes, and distributor transactions were considered when reliable data were available.
• Final estimates were validated against primary interviews, company disclosures, procurement evidence, regulatory records, and the scope definitions used throughout the analysis.

13. Overall Market Estimation Framework

The final U.S. market estimate was developed through the following sequence:

1. Define the products and services included in image-guided therapy systems.
2. Identify relevant manufacturers, product categories, and healthcare end users.
3. Estimate annual unit sales, installed-base replacements, and average selling prices.
4. Calculate eligible software, upgrade, and service revenue without double counting.
5. Build an independent top-down estimate using relevant medical technology market data and attributable revenue shares.
6. Validate assumptions through company disclosures, FDA records, procurement information, and expert interviews.
7. Reconcile both approaches and prepare historical estimates, segment shares, and forecasts.

Core market formula:

• Total Market Revenue = Equipment Revenue + Eligible Software Revenue + Eligible Service and Upgrade Revenue

Important: The final estimate should include only revenue attributable to the defined image-guided therapy systems market. Broader diagnostic imaging, unrelated surgical equipment, procedure fees, and overlapping bundled revenue should not be added automatically.

Market Segmentations

Product

• Endoscope
• Magnetic Resonance Imaging
• Computed Tomography Scanners
• Ultrasound Systems
• X-Rat Fluoroscopy
• Single Photon Emission Computed Tomography
• Positron Emission Tomography

Application

• Cardiac Surgery
• Neurosurgery
• Orthopedic Surgery
• Urology
• Gastroenterology
• Oncology Surgery
• Others

End Use

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Research & Academic Institutions

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis:

• Siemens Healthineers
• Koninklijke Philips
• General Electric Company
• Brainlab
• Medtronic Plc
• Olympus Corporation
• KARL STORZ SE & Co. KG
• Stryker Corporation

Report Details: